How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

49,122 results for

prostate AND cancer

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study

Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from (...) the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Adding multiparametric MRI as an initial test prior to prostate biopsy can reduce the proportion of men having unnecessary biopsies and improve the detection of clinically significant prostate cancer. {{author}} {{($index , , , , , , , , , , , , , , , , , , , , , , , , , & . Louise Clare Brown 1 , Hashim U Ahmed 2, 3, * , Rita

2018 NIHR HTA programme

2. Prostate cancer screening with prostate-specific antigen (PSA) test Full Text available with Trip Pro

Prostate cancer screening with prostate-specific antigen (PSA) test Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline | The BMJ Intended for healthcare professionals Username * Password * Edition: Search form Search Search Prostate cancer... Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline CC BY NC Open access (Published 05 September 2018) Cite this as: BMJ 2018;362:k3581 Population Diagnostic (...) pathway for prostate cancer Localised Stage I or II Stage III or IV Advanced Abnormal biopsy and staging No cancer diagnosis Normal biopsy Still possible to have a biopsy and be diagnosed, based on clinical suspicion No Biopsy Biopsy Normal PSA Elevated PSA or Choices considered in this comparison Prostate-specific antigen (PSA) screening No PSA screening Width of lines proportional to approximate numbers of people Subsequent treatment Surgery Radiation Active surveillance With or without hormonal

2018 BMJ Rapid Recommendations

3. Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. (Abstract)

Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Multiparametric magnetic resonance imaging (MRI), with or without MRI-targeted biopsy, is an alternative test to systematic transrectal ultrasonography-guided biopsy in men suspected of having prostate cancer. At present, evidence on which test to use is insufficient to inform detailed evidence-based decision-making.To determine the diagnostic accuracy of the index tests MRI only, MRI (...) -targeted biopsy, the MRI pathway (MRI with or without MRI-targeted biopsy) and systematic biopsy as compared to template-guided biopsy as the reference standard in detecting clinically significant prostate cancer as the target condition, defined as International Society of Urological Pathology (ISUP) grade 2 or higher. Secondary target conditions were the detection of grade 1 and grade 3 or higher-grade prostate cancer, and a potential change in the number of biopsy procedures.We performed

2019 Cochrane

4. Prostate-Specific Antigen Testing for Prostate Cancer: Clinical Utility and Guidelines

Prostate-Specific Antigen Testing for Prostate Cancer: Clinical Utility and Guidelines Prostate-Specific Antigen Testing for Prostate Cancer: Clinical Utility and Guidelines | CADTH.ca Find the information you need Prostate-Specific Antigen Testing for Prostate Cancer: Clinical Utility and Guidelines Prostate-Specific Antigen Testing for Prostate Cancer: Clinical Utility and Guidelines Last updated: August 22, 2019 Project Number: RA1060-000 Product Line: Research Type: Devices and Systems (...) Report Type: Reference List Result type: Report Question What is the clinical utility of prostate-specific antigen testing for prostate cancer? What are the evidence-based guidelines on the use of prostate-specific antigen testing for prostate cancer screening? Key Message Two systematic reviews were identified regarding the clinical utility of prostate-specific antigen testing for prostate cancer. In addition, five evidence-based guidelines were identified regarding the use of prostate-specific

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

5. The clinical effectiveness and cost-effectiveness of the PROGENSA prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation

The clinical effectiveness and cost-effectiveness of the PROGENSA prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation Journals Library An error occurred retrieving content to display, please try

2015 NIHR HTA programme

6. Fluorine- or gallium- prostate-specific membrane antigen (PSMA) positron emission tomography (PET) radiotracers in the investigation of recurrent prostate cancer

Fluorine- or gallium- prostate-specific membrane antigen (PSMA) positron emission tomography (PET) radiotracers in the investigation of recurrent prostate cancer Fluorine- or gallium- prostate-specific membrane antigen positron emission tomography radiotracers - Health Technology Wales > Fluorine- or gallium- prostate-specific membrane antigen positron emission tomography radiotracers Fluorine- or gallium- prostate-specific membrane antigen positron emission tomography radiotracers Topic Status (...) Incomplete Fluorine- or gallium- prostate-specific membrane antigen (PSMA) positron emission tomography (PET) radiotracers in the investigation of recurrent prostate cancer. Outcome of the appraisal The adoption of 68 Ga prostate-specific membrane antigen (PSMA) positron emission tomography (PET) for the diagnosis of recurrent prostate cancer is partially supported by the evidence. The use of 68 Ga PSMA PET provides a high degree of diagnostic accuracy on which to base management decisions as compared

2019 Health Technology Wales

7. Prostate cancer: diagnosis and management

Prostate cancer: diagnosis and management Prostate cancer: diagnosis and Prostate cancer: diagnosis and management management NICE guideline Published: 9 May 2019 www.nice.org.uk/guidance/ng131 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When (...) with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Prostate cancer: diagnosis and management (NG131) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 51Contents Contents Overview 4 Who is it for? 4 Recommendations 5

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

8. Axumin for functional imaging of prostate cancer recurrence

Axumin for functional imaging of prostate cancer recurrence Axumin for functional imaging of prostate cancer Axumin for functional imaging of prostate cancer recurrence recurrence Medtech innovation briefing Published: 8 February 2019 nice.org.uk/guidance/mib172 pathways Summary Summary The technology technology described in this briefing is Axumin, a radiopharmaceutical agent. It is intended for use in positron emission tomography (PET) to detect suspected prostate cancer recurrence in people (...) who have elevated prostate-specific antigen levels after primary curative treatment. It is currently the only licensed PET tracer indicated for use in recurrent prostate cancer. The inno innovativ vative aspects e aspects are that it is a prostate cancer-specific PET tracer with a novel mechanism of action based on amino acid transport. Its longer half-life and shorter uptake period may allow use in more people with suspected prostate cancer recurrence compared with other PET tracers. The intended

2019 National Institute for Health and Clinical Excellence - Advice

9. Randomised controlled trial: Similar prostate cancer and all-cause mortality in men with localised prostate cancer undergoing surgery or radiation therapy versus active monitoring at 10?years of follow-up

Randomised controlled trial: Similar prostate cancer and all-cause mortality in men with localised prostate cancer undergoing surgery or radiation therapy versus active monitoring at 10?years of follow-up Similar prostate cancer and all-cause mortality in men with localised prostate cancer undergoing surgery or radiation therapy versus active monitoring at 10 years of follow-up | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you (...) prostate cancer and all-cause mortality in men with localised prostate cancer undergoing surgery or radiation therapy versus active monitoring at 10 years of follow-up Article Text Therapeutics/Prevention Randomised controlled trial Similar prostate cancer and all-cause mortality in men with localised prostate cancer undergoing surgery or radiation therapy versus active monitoring at 10 years of follow-up Philipp Dahm 1 , 2 , Dragan Ilic 3 , Timothy Wilt 4 , 5 Statistics from Altmetric.com Commentary

2017 Evidence-Based Medicine

10. Padeliporfin (Tookad) - prostate cancer / Prostatic Neoplasms

Padeliporfin (Tookad) - prostate cancer / Prostatic Neoplasms 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 14 September 2017 EMA/644309/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment report TOOKAD International non-proprietary name: padeliporfin Procedure No. EMEA/H/C/004182/0000 Note Assessment report (...) an application for marketing authorisation to the European Medicines Agency (EMA) for Tookad, through the centralised procedure falling within the Article 3(1) and point 3 of Annex of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 26 March 2015. The applicant applied for the following indication: Tookad is indicated for the treatment of low-risk localised prostate cancer. Tookad is indicated in adult males. The legal basis for this application

2017 European Medicines Agency - EPARs

11. Enzalutamide for hormone-relapsed non-metastatic prostate cancer

Enzalutamide for hormone-relapsed non-metastatic prostate cancer Enzalutamide for hormone-relapsed non- Enzalutamide for hormone-relapsed non- metastatic prostate cancer metastatic prostate cancer T echnology appraisal guidance Published: 15 May 2019 www.nice.org.uk/guidance/ta580 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent (...) inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Enzalutamide for hormone-relapsed non-metastatic prostate cancer (TA580) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 21Contents Contents 1 Recommendations 4 2 Information about

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

12. Prostate cancer

Prostate cancer Evidence Maps - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4

2018 Trip Evidence Maps

13. Partial ablation versus radical prostatectomy in intermediate-risk prostate cancer: the PART feasibility RCT

Partial ablation versus radical prostatectomy in intermediate-risk prostate cancer: the PART feasibility RCT Partial ablation versus radical prostatectomy in intermediate-risk prostate cancer: the PART feasibility RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you (...) need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Randomisation of men to a RCT comparing partial prostate ablation and radical prostatectomy is feasible. {{author}} {{($index , , , , , , , , , , , , , , , , , , , , & . Freddie C Hamdy 1, * , Daisy Elliott 2 , Steffi le Conte 1 , Lucy C Davies 3 , Richéal M Burns 3 , Claire Thomson 1 , Richard Gray 3 , Jane Wolstenholme 3 , Jenny L Donovan 2, 4 , Ray Fitzpatrick 3 , Clare Verrill 1 , Fergus

2018 NIHR HTA programme

14. Padeliporfin for untreated localised prostate cancer

Padeliporfin for untreated localised prostate cancer P Padeliporfin for untreated localised adeliporfin for untreated localised prostate cancer prostate cancer T echnology appraisal guidance Published: 21 November 2018 nice.org.uk/guidance/ta546 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE, arrived at after (...) and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Padeliporfin for untreated localised prostate cancer (TA546) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 17Contents Contents 1 Recommendations 4 2 Information about padeliporfin 6 3 Committee discussion 7

2018 National Institute for Health and Clinical Excellence - Technology Appraisals

15. Hypofractionation for clinically localized prostate cancer. (Abstract)

Hypofractionation for clinically localized prostate cancer. Using hypofractionation (fewer, larger doses of daily radiation) to treat localized prostate cancer may improve convenience and resource use. For hypofractionation to be feasible, it must be at least as effective for cancer-related outcomes and have comparable toxicity and quality of life outcomes as conventionally fractionated radiation therapy.To assess the effects of hypofractionated external beam radiation therapy compared (...) result in little or no difference in prostate cancer-specific survival [PC-SS] (HR 1.00, 95% CI 0.72 to 1.39; studies = 8, participants = 7946; median follow-up 72 months; low-certainty evidence). For men in the intermediate-risk group undergoing conventional fractionation this corresponds to 976 per 1000 men alive after 6 years and 0 more (44 fewer to 18 more) alive per 1000 men undergoing hypofractionation.We are uncertain about the effect of hypofractionation on late radiation therapy

2019 Cochrane

16. Interstitial low-dose-rate brachytherapy for localized prostate cancer - rapid report

Interstitial low-dose-rate brachytherapy for localized prostate cancer - rapid report 1 Translation of the key statement of the rapid report N17-04 Interstitielle Low-Dose-Rate-Brachytherapie beim lokal begrenzten Prostatakarzinom (Version 1.0; Status: 19 October 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding (...) . Extract IQWiG Reports – Commission No. N17-04 Interstitial low-dose-rate brachytherapy for localized prostate cancer 1 Extract of rapid report N17-04 Version 1.0 Brachytherapy for prostate cancer 19 October 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Interstitial low-dose-rate brachytherapy for localized prostate cancer Commissioning agency: Federal Joint Committee Commission awarded

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

17. Early versus deferred standard androgen suppression therapy for advanced hormone-sensitive prostate cancer. (Abstract)

Early versus deferred standard androgen suppression therapy for advanced hormone-sensitive prostate cancer. Standard androgen suppression therapy (AST) using surgical or medical castration is considered a mainstay of advanced hormone-sensitive prostate cancer treatment. AST can be initiated early when disease is asymptomatic or deferred when patients suffer symptoms of disseminated prostate cancer.To assess the effects of early versus deferred standard AST for advanced hormone-sensitive (...) AST. We excluded all other study designs. Participants included had advanced hormone-sensitive prostate cancer receiving surgical or medical castration.Two review authors independently classified studies and abstracted data. The primary outcomes were time to death of any cause and serious adverse events. Secondary outcomes were time to disease progression, time to death from prostate cancer, adverse events and quality of life. We performed statistical analyses using a random-effects model

2019 Cochrane

18. Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer

Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer CUAJ • February 2020 • Volume 14, Issue 2 © 2020 Canadian Urological Association CUA gUideline 17 Cite as: Can Urol Assoc J 2020;14(2):17-23. http://dx.doi.org/10.5489/cuaj.6384 Published online December 5, 2019 Introduction Metastatic prostate cancer remains an incurable disease. In Canada, approximately 8% of men with prostate cancer are diagnosed (...) de novo with metastatic disease and, in 2018, roughly 1200 men were diagnosed with de novo metastat- ic prostate cancer (PC). 1 The mainstay of treatment for de novo metastatic PC is androgen-deprivation therapy (ADT), which is initially effective in almost all patients. Progression is inevitable, however, heralded by a rise in prostate-specific antigen (PSA), increasing disease burden, and/or worsening symptoms — a disease state called metastatic castration- resistant prostate cancer (mCRPC

2020 Canadian Urological Association

19. Abiraterone acetate (prostate cancer) - Addendum to Commission A17-64

Abiraterone acetate (prostate cancer) - Addendum to Commission A17-64 1 Translation of addendum A18-26 Abirateronacetat (Prostatakarzinom) – Addendum zum Auftrag A17-64 (Version 1.0; Status: 11 May 2018). Please note: This translation is provided as a service by IQWiG to English- language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 11 May 2018 1.0 Commission: A18-26 Version: Status: IQWiG Reports – Commission No. A18-26 Abiraterone (...) acetate (prostate cancer) – Addendum to Commission A17-64 1 Addendum A18-26 Version 1.0 Abiraterone acetate – Addendum to Commission A17-64 11 May 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Abiraterone acetate (prostate cancer) – Addendum to Commission A17-64 Commissioning agency: Federal Joint Committee Commission awarded on: 25 April 2018 Internal Commission No.: A18-26 Address

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

20. Abiraterone acetate (prostate cancer) - Benefit assessment according to §35a Social Code Book V

Abiraterone acetate (prostate cancer) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Abirateronacetat (Prostatakarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 13 March 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A17-64 (...) Abiraterone acetate (prostate cancer) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-64 Version 1.0 Abiraterone acetate (prostate cancer) 13 March 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Abiraterone acetate (prostate cancer) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>